We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Tau Radiotracer Aids Alzheimer's Disease Diagnosis

By MedImaging International staff writers
Posted on 11 Jun 2020
Print article
A novel diagnostic radiotracer can help estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adults being evaluated for Alzheimer’s disease (AD).

Developed by Avid Radiopharmaceuticals (Philadelphia, PA, USA), a wholly owned subsidiary of Eli Lilly (Indianapolis, IN, USA), Tauvid (flortaucipir 18F) radiotracer is a small-molecule selective positron emission tomography (PET) imaging agent that binds to aggregated tau protein, which in the brains of patients with AD, combine to form NFTs, one of the two components required for the neuropathological diagnosis of AD. The safety and effectiveness of the tau tracer were demonstrated in two clinical studies.

The first study included 156 terminally ill patients who agreed to undergo Tauvid PET imaging and to donate their brains after death; 64 died within nine months of brain scanning. Five evaluators' readings were then compared to post mortem readings from independent pathologists, who were blinded to the PET scan results. The results showed that the five evaluator’s readings had a high probability of correctly evaluating patients with tau pathology and had an average-to-high probability of correctly evaluating patients without tau pathology.

The second study included the same patients with terminal illness that participated in the first study, but with an additional 18 patients with terminal illness and 159 patients with cognitive impairment who were being evaluated for AD. In this second study, reader agreement was 0.87 across all 241 patients. In a separate subgroup analysis that included the 82 terminally ill patients who were diagnosed after death and the 159 patients with cognitive impairment, reader agreement was 0.90 for the AD patients and 0.82 in the terminally ill patients.

“The fight against Alzheimer’s disease requires precise and reliable assessments of the two key pathologies of the disease, because clinical assessments alone are limited in their ability to accurately diagnose patients,” said Mark Mintun, MD, vice president of Lilly's pain and neurodegeneration research and development. “Lilly and Avid Radiopharmaceuticals are committed to bringing innovative AD diagnostics to the patients who need them most.”

“Diagnostic imaging can help patients and their families plan for the future and make informed choices about their health and well-being, in addition to facilitating appropriate patient management for physicians,” said professor of neurology Reisa Sperling, MD, of Harvard Medical School (Boston, MA, USA). “Determining the anatomic distribution and density of tau NFTs in the brain was previously possible only at autopsy. Now we have a way to obtain this important information in patients.”

18F is a fluorine radioisotope that decays by positron emission 97% of the time, and electron capture 3% of the time; both modes of decay yield stable oxygen-18 (18O). 18F is an important radioisotope as a result of both its short half-life and the emission of positrons when decaying. It is primarily synthesized into fluorodeoxyglucose (FDG) for use in PET scans.

Related Links:
Avid Radiopharmaceuticals
Eli Lilly


Gold Supplier
Premium Ultrasound Scanner
ARIETTA 850
New
Crossover Angiography System
Trinias C16s/C12s/F12s
New
Ceiling-Mounted Digital X-Ray System
DigitalDiagnost C50
New
Radiography System
NovaT

Print article

Channels

MRI

view channel
Image: New scan measures tumor oxygen levels in real-time to help guide treatment (Photo courtesy of ICR)

Oxygen-Enhanced MRI Technology Allows Cancer Doctors to See Inside Tumors

Since the 1950s, researchers have been aware of the difficulty in effectively treating tumors deprived of oxygen, a problem that is further exacerbated when treating them with radiotherapy.... Read more

Ultrasound

view channel
Image: New focused ultrasound is effective for treating Parkinson’s, movement disorders (Photo courtesy of Pexels)

New Focused Ultrasound Treatment Proves Effective for Parkinson’s Disease Patients

Parkinson's disease is a neurological condition characterized by the loss of dopamine neurons within the brain. While medications such as levodopa can be effective in managing this condition, some patients... Read more

General/Advanced Imaging

view channel
Image: Viz.ai is the first to receive FDA 510(k) clearance for an AI algorithm for abdominal aortic aneurysm (Photo courtesy of Pexels)

AI Algorithm Flags and Triages Suspected Abdominal Aortic Aneurysms from Chest CT Scans

An abdominal aortic aneurysm (AAA) denotes a bulge in the abdominal aorta, the chief artery that transfers blood from the heart to other parts of the body. If not detected and treated in time, AAA can... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.